Marked Improvement in Detecting the Number of Involved Nodal Areas in Lymphoma, Using 18 F- FDG - PET and CT Scan.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1344-1344
Author(s):  
Juan Chalapud ◽  
Pedro Sobrevilla-Calvo ◽  
Silvia Rivas-Vera ◽  
Javier Altamirano-Levy

Abstract Positron emission tomography (PET) imaging with 18-fluoro-2-deoxiglucose (FDG) is used increasingly for the initial evaluation and staging of patients with Hodgkin’s lymphoma (HL) and non- Hodgkin’s lymphoma (NHL). However, the degree of concordance of PET and TAC scanning for each nodal and extra nodal site are not well defined. The number of nodal areas involved is a new prognostic factor in follicular lymphomas as was demonstrated in the Follicular Lymphoma (FL) International prognostic index (FLIPI), and their use may be useful for the LNH and HL. In this study, we examined the performance of CT versus FDG-PET scanning, comparing each one of the nodal and extra nodal areas, as it is described in the FLIPI, in a retrospective cohort of lymphoma patients (pts) with HL and NHL. We reviewed the charts of 56 patients with diagnosis of HL and NHL in the initial and relapse staging, in a single tertiary care center. All patients had FDG-PET imaging study, clinical examination and CT scans. The Ann Arbor stage, each nodal site (cervical, mediastinal, axillary, mesenteric, para aortic, inguinal), and extra nodal sites were evaluated on the basis of FDG-PET scanning and were compared with the findings derived from CT. Bone marrow biopsy results were excluded from this initial analysis. The histopathological diagnoses included diffuse large B-cell Lymphomas in 20/56 pts (36%), HL 15/56 pts (27%), anaplastic large cell lymphoma 8/56 pts (14%), FL 5/56 pts (9%), peripheral T-cell Lymphoma 4/56 (7%) and others 7%. Among the 56 pts, 22 (39%) had discordant results between FDG-PET scanning and CT scanning, that lead to a change in stage assignment. Among the discordant cases FDG-PET resulted in upstaging in 18/56 pts (32%), and down staging in 4/56 pts (7%). Forty for pts (79%) had discordant results in the number of nodal areas, among the discordant cases FDG-PET detected more nodal areas in 36/56 pts (64%) and CT in 8/56 pts (14%). The discordant cases were distributed as it is shown in the table. In conclusion Pet and CT in combination detects more involved nodal areas than each method by itself. Summary of PET/CT correlation with nodal areas Nodal areas Cervical(n) Axillar (n) Mediastinal(n) Paraaortic(n) Inguinal (n) positive total 40 26 26 24 17 Only Positive FDG-PET 16 12 13 7 11 Only Positive CT 7 3 2 2 1 Positive FGD-PET + CT 17 11 11 15 5

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4949-4949
Author(s):  
Blanca Sanchez-Gonzalez ◽  
Carlos Trampal ◽  
Alberto Solano ◽  
Carmen Pedro ◽  
Jm Maiques ◽  
...  

Abstract BACKGROUND: 18-Fluoro-deoxyglucose positron emission tomography (FDG-PET) is a noninvasive imaging tool for initial staging and evaluation of treatment response in Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). PET imaging can provide additional information to conventional imaging as computer tomography (CT). AIM: The aim of this study was to evaluate the role of PET in improving the staging and if this fact could have an impact in prognosis, in compared to CT. METHODS: From February 2005 to January 2008, one hundred ten consecutive patients with NHL (49 aggressive, 32 indolent and 3 unclassifficated) and HL (26 patients) were staged according to the Ann Arbor classification with CT and bone marrow biopsy (BMb). As well, all patients underwent to FDG-PET body before treatment. International Prognostic Index (IPI) was calculated following standard staging (IPI-st) and with standard staging plus FDG-PET (IPI-PET) in NHL. RESULTS: CT and FDG-PET were concordant in 84 patients (66%). In 37 patients (34%) discordance was observed: in 7 patients FDG-PET was negative, in 11 patients FDG-PET detected more bone lesions, in 11 patients FDGPET uptake in other lymph nodes, including spleen infiltration, and in 8 patients FDGPET detected less lymph nodes or organ involvement. However, additional information of FDG-PET changed in staging in 21 out of 37 patients with discordant findings but the IPI risk changed in only 5 patients. Discrepancies CT and FDG-PET were seen in similar proportion in all lymphoma subtypes. Overall survival curves at two years showed no differences between IPI-st and IPI-PET (IPI-st 0–1: 97%, 2–3: 89%, 4–5: 48%; IPI-PET 0–1: 96%, 2–3: 89%, 4–5: 48% ). CONCLUSIONS: FDG-PET can provide additional information to CT in both aggressive or indolent non-Hodgkin lymphoma and Hodgkin lymphoma. CT and FDG-PET were discordant in 30 % of the patients but only half of them showed change of stage. IPI risk was modified in few patients with NHL. Inclusion of patients is ongoing.


2018 ◽  
Vol 39 (6) ◽  
pp. 572-578 ◽  
Author(s):  
Rayan H.M. Alkhawtani ◽  
Walter Noordzij ◽  
Andor W.J.M. Glaudemans ◽  
Rozemarijn S. van Rijn ◽  
Hilde T. van der Galiën ◽  
...  

Author(s):  
Volkan Bas ◽  
Elif Gulsum Umit ◽  
Ulku Korkmaz ◽  
Mehmet Baysal ◽  
Sedanur Karaman Gulsaran ◽  
...  

2019 ◽  
Vol 76 ◽  
pp. 48-52
Author(s):  
Martina Panebianco ◽  
Oreste Bagni ◽  
Natalia Cenfra ◽  
Sergio Mecarocci ◽  
Elettra Ortu La Barbera ◽  
...  

Author(s):  
Piyush Aggarwal ◽  
Anwin Joseph Kavanal ◽  
Harmandeep Singh ◽  
Rajender Kumar ◽  
Rajeev Ranjan ◽  
...  

Blood ◽  
1995 ◽  
Vol 86 (4) ◽  
pp. 1460-1463 ◽  
Author(s):  
J Hermans ◽  
AD Krol ◽  
K van Groningen ◽  
PM Kluin ◽  
JC Kluin-Nelemans ◽  
...  

An International Prognostic Index (IPI) for patients with aggressive non-Hodgkin's lymphoma (NHL) has recently been published. The IPI is based on pretreatment clinical characteristics and developed on clinical trial patients, classified as intermediate grade according to the Working Formulation (WF). We applied this IPI in a population-based registry of NHL patients. This registry does not have the restrictions that usually hold for patients in clinical trials, eg, with respect to age and performance status. Moreover, it covers all the three WF classes (low, intermediate, and high). The IPI turned out to be of prognostic value for response rate and survival in our unselected cohort of 744 patients, as well. In each of the three WF classes separately, the four IPI classes showed going from low to high substantially decreasing response rates and survival percentages. For our cohort of WF intermediate grade patients 5-year survival levels were lower in all four IPI classes (59%, 34%, 14%, and 10%, respectively), probably reflecting the selection of clinical trial patients in the original study (73%, 51%, 43%, and 26%).


Sign in / Sign up

Export Citation Format

Share Document